Pfizer Plans Filing as Vaccine Proves 95% Effective (2)

Nov. 18, 2020, 4:38 PM

Pfizer Inc. said a final analysis of clinical-trial data showed its Covid-19 vaccine was 95% effective, paving the way for the company to apply this week for the first U.S. regulatory authorization for a coronavirus shot.

The U.S. drugmaker and partner BioNTech SE said their vaccine protected people of all ages and ethnicities, with no significant safety problems so far in a trial that includes almost 44,000 participants.

Pfizer shares were up 2% at 11:25 a.m. in New York, with BioNTech American depositary receipts gaining 5.3%.

The update is the latest in a string of promising developments on the vaccine ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.